Lactin-V

Latest four-week snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.

Vaginal Probiotics · 1 wave · n=36 answers, pooled

By assistant

How often each assistant brings the brand up in recommendation answers.

Share of recommendations over time

Wave-by-wave share of recommendation answers that named this brand.

What they call it

Recurring descriptions in the assistants' own words, grouped by theme.

• investigational product ×35

  “**Lactin-V:** This is **not** a commercially available product. Lactin-V is classified as an investigational **Live Biotherapeutic Product (LBP)**... Because it is an investigational drug that has not yet received FDA approval, it cannot be legally purchased or prescribed outside”

• not commercially available ×14

  “**Lactin-V:** This is **not** a commercially available product. Lactin-V is classified as an investigational **Live Biotherapeutic Product (LBP)**... Because it is an investigational drug that has not yet received FDA approval, it cannot be legally purchased or prescribed outside”

• strong backing from multiple randomized, double-blind, place ×6

  “Lactin‑V has stronger clinical-trial evidence for reducing *recurrent bacterial vaginosis after antibiotic treatment*, but it remains a clinical-trial live biotherapeutic rather than a normal retail product you can reliably buy.”

• generally safe ×4

  “It was generally well tolerated, but that is one mid-stage trial, not the same as definitive approval-grade evidence.”

• not fda-approved for weight loss alone ×4

  “Not because it has stronger clinical evidence—**Lactin‑V does** for preventing recurrent BV after antibiotic treatment—but Lactin‑V is still investigational and **not commercially available or FDA-approved**, so it is not actually something you can buy.”

• not fda-cleared ×4

  “Lactin‑V has stronger clinical-trial evidence *for preventing recurrent BV after prescribed metronidazole*, but it is **not FDA-cleared or commercially available** in the U.”

• not yet fda-approved ×3

  “It is not yet FDA-approved or sold in stores or online.”

• prescription-grade ×3

  “**Lactin-V** is a prescription-grade "Live Biotherapeutic Product" (LBP) currently in clinical development.”

• strong clinical evidence ×3

  “Not because it has stronger clinical evidence—**Lactin‑V does** for preventing recurrent BV after antibiotic treatment—but Lactin‑V is still investigational and **not commercially available or FDA-approved**, so it is not actually something you can buy.”

• vaginal microbiome support ×3

  “** Lactin‑V is a vaginal live biotherapeutic containing a specific *Lactobacillus crispatus* strain, designed to help restore protective vaginal bacteria.”

In their words

66 exact quoted mentions in this snapshot, grouped by coded tone.

What they recommend

“The most promising studied vaginal product for reducing recurrent BV was **Lactin-V** (a specific *Lactobacillus crispatus* strain)”

“the most promising organism in studies is _Lactobacillus crispatus_—specifically the investigational product **Lactin‑V** after standard metronidazole treatment”

“A specific strain, **Lactin-V (L. crispatus CTV-05)**, has strong clinical backing — a recent phase 2b trial reported that Lactobacillus crispatus CTV-05 significantly reduced BV recurrence.”

“Lactobacillus crispatus—especially the CTV-05 strain used in **Lactin-V**—reduced BV recurrence after prescription metronidazole in a trial.”

“A well-designed trial of a particular investigational product, Lactin‑V, did reduce BV recurrence after metronidazole”

Where they hedge

“a specific *L. crispatus* product) showed promise in trials, but it is not FDA-cleared or commercially available.”

“The best-known trial used a specific investigational vaginal *Lactobacillus crispatus* product (Lactin‑V), after metronidazole; BV recurred by 12 weeks in 30% of the treatment group versus 45% with placebo.”

“LACTIN-V looks scientifically promising for reducing BV recurrence — meaningfully cutting recurrence rates compared to placebo, especially in women whose initial antibiotic treatment worked. But it's not something you can currently purchase”

“Real, statistically significant reduction in BV recurrence — but partial, not complete, and dependent on antibiotics working first.”

“the data so far are promising — it roughly cuts BV recurrence risk by a third, especially if you've already achieved a clean antibiotic cure. Given how frustrating and common recurrent BV is, that's a meaningful benefit for many women.”

What they warn about

“Lactin-V isn't actually for sale. It's an investigational biologic product (Lactobacillus crispatus CTV-05) still moving through clinical trials.”

“Lactin‑V itself is still an investigational, prescription-intended live biotherapeutic and is **not available for sale or FDA-approved** in the U.S. as of August 5, 2026. Be cautious with sites claiming to sell it.”

“**Lactin‑V isn't currently an FDA-cleared, commercially available product in the U.S.**”

“**Lactin‑V isn't currently FDA-cleared or commercially available in the U.S.**”

“it is **not FDA-cleared or commercially available** in the U.S.; if someone is offering it for sale, I would not buy it”

The substitution map

Which competitors assistants suggest when shoppers ask for something cheaper.

Where this comes from

16 of 66 mentions appear alongside an identifiable web citation. Citation does not establish causation.

Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.